Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Dosage_and_Administration_ABRAX

Annotations (1)

- rdfs:comment "Do not substitute ABRAXANE for other paclitaxel products. (2.1) • Extravasation: Closely monitor the infusion site for extravasation and infiltration. (2.1) • Metastatic Breast Cancer (MBC): Recommended dosage of ABRAXANE is 260 mg/m2 intravenously over 30 minutes every 3 weeks. (2. 2) • Non-Small Cell Lung Cancer (NSCLC): Recommended dosage of ABRAXANE is 100 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE. (2.2) • Adenocarcinoma of the Pancreas: Recommended dosage of ABRAXANE is 125 mg/m2 intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE. (2.4) • Use in Patients with Hepatic Impairment: ABRAXANE is not recommended for use in patients with AST > 10 x ULN; or bilirubin > 5 x ULN or with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For MBC or NSCLC, reduce starting dose in patients with moderate to severe hepatic impairment. (2.5)
Dose Reductions for Adverse Reactions: Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities. (2.6)"(xsd:string)

Superclasses (1)

- '\'Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_\''

Disjoints (8)

Adverse_Reactions_ABRAX, Contraindications_ABRAX, **Dosage_and_Administration_ABRAX**, Dosage_Forms_and_Strengths_ABRAX, Drug_Interactions_ABRAX, Indications_and_Usage_ABRAX, Use_in_Specific_Populations_ABRAX, Warnings_and_Precautions_ABRAX

OWL HTML inside